Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures~* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening~* No prior use of any approved or investigational antiretroviral drug for any length of time, except the use for pre-exposure prophylaxis (PREP), or post-exposure prophylaxis (PEP) up to 6 months prior to screening~* Screening genotype report must show sensitivity to elvitegravir, emtricitabine, tenofovir DF~* Normal electrocardiogram (ECG)~* Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the Cockcroft-Gault formula for creatinine clearance~* Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)~* Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin~* Adequate hematologic function~* Serum amylase ≤ 5 × ULN~* Males and females of childbearing potential must agree to utilize highly effective contraception methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following the last dose of study drug~* Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing~* Females who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level at screening within the post-menopausal range based on the Central Laboratory reference range~* Age ≥ 18 years~Key Exclusion Criteria:~* A new AIDS-defining condition diagnosed within the 30 days prior to screening~* Hepatitis B surface antigen (HBsAg) positive~* Hepatitis C antibody positive~* Individuals experiencing decompensated cirrhosis~* Females who are breastfeeding~* Positive serum pregnancy test~* Have an implanted defibrillator or pacemaker~* Current alcohol or substance use judged by the Investigator to potentially interfere with study compliance~* History of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma~* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline~* Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements~* Participation in any other clinical trial (including observational trials) without prior approval~* Receiving ongoing therapy with drugs not to be used with elvitegravir, cobicistat, emtricitabine, tenofovir DF, and TAF or participants with any known allergies to the excipients of E/C/F/TDF or E/C/F/TAF~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- E/C/F/TAF (Double-Blind) (Type: EXPERIMENTAL): E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded.
- E/C/F/TDF (Double-Blind) (Type: ACTIVE_COMPARATOR): E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded.
- Open-Label E/C/F/TAF (Type: EXPERIMENTAL): After the unblinding visit, in countries where E/C/F/TAF is not commercially available, participants (except in UK) who complete 144 weeks of study will be given the option to receive open-label E/C/F/TAF and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.

Based on this trial design, predict the completion outcome and termination type (if applicable).